ArticleScientific reports2026
Adaptive neighborhood aggregation graph neural network for early diagnosis of Alzheimer's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Early diagnosis of Alzheimer's disease (AD) is crucial for timely intervention but remains challenging due to subtle and heterogeneous brain alterations, particularly in the mild cognitive impairment (MCI) stage. To address this issue, we propose a pathology-aware Adaptive Neighborhood Aggregation Graph Neural Network (ANA-GNN) to model the brain as a dynamic and task-driven graph for multimodal AD classification. The framework integrates three synergistic components: an adaptive neighborhood aggregation module that aligns each node's receptive field with disease-specific heterogeneity, an importance-weighted pooling mechanism that enhances discriminative graph-level representations by prioritizing biologically relevant regions, and a gated multimodal fusion strategy that adaptively balances imaging and non-imaging information. Evaluated on an expanded cohort of 707 subjects from the ADNI dataset, ANA-GNN achieved an overall accuracy of 85.23% and an F1-score of 85.44%, consistently outperforming state-of-the-art baselines such as BrainGNN and Graph Transformers. Furthermore, the identified high-importance brain regions, including the hippocampus, amygdala, and posterior cingulate cortex, align with known AD biomarkers, demonstrating the model's biological interpretability and potential as a reliable tool for early AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.